BACKGROUND: In 2000 we launched a prospective program of intersphincteric resection (ISR) for very low rectal cancer. In this study we compared the oncologic outcome of patients who underwent ISR with the outcome of patients who underwent abdominoperineal resection (APR). METHODS: The data of 202 patients with very low rectal cancer who underwent curative ISR (n = 132) or curative APR (n = 70) between 1995 and 2006 were analyzed. Patients were divided into ISR and APR groups. Survival and local recurrence were investigated in both groups. RESULTS: The median follow-up was 40 months in the ISR group and 57 months in the APR group. The 5-year local relapse-free survival rate was 83% in the ISR group and 80% in the APR group (p = 0.364), and the 5-year disease-free survival rate was 69% in the ISR group and 63% in the APR group (p = 0.714). CONCLUSIONS: For very low rectal cancers, ISR appears to be oncologically acceptable and can reduce the number of APRs.
BACKGROUND: In 2000 we launched a prospective program of intersphincteric resection (ISR) for very low rectal cancer. In this study we compared the oncologic outcome of patients who underwent ISR with the outcome of patients who underwent abdominoperineal resection (APR). METHODS: The data of 202 patients with very low rectal cancer who underwent curative ISR (n = 132) or curative APR (n = 70) between 1995 and 2006 were analyzed. Patients were divided into ISR and APR groups. Survival and local recurrence were investigated in both groups. RESULTS: The median follow-up was 40 months in the ISR group and 57 months in the APR group. The 5-year local relapse-free survival rate was 83% in the ISR group and 80% in the APR group (p = 0.364), and the 5-year disease-free survival rate was 69% in the ISR group and 63% in the APR group (p = 0.714). CONCLUSIONS: For very low rectal cancers, ISR appears to be oncologically acceptable and can reduce the number of APRs.
Authors: E Kapiteijn; C A Marijnen; I D Nagtegaal; H Putter; W H Steup; T Wiggers; H J Rutten; L Pahlman; B Glimelius; J H van Krieken; J W Leer; C J van de Velde Journal: N Engl J Med Date: 2001-08-30 Impact factor: 91.245
Authors: N Saito; K Koda; K Nobuhiro; K Takiguchi; K Oda; H Soda; M Nunomura; H Sarashina; N Nakajima Journal: World J Surg Date: 1999-10 Impact factor: 3.352
Authors: Johannes Klose; Ignazio Tarantino; Yakup Kulu; Thomas Bruckner; Stefan Trefz; Thomas Schmidt; Martin Schneider; Thilo Hackert; Markus W Büchler; Alexis Ulrich Journal: J Gastrointest Surg Date: 2016-12-15 Impact factor: 3.452